{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:13:01Z","timestamp":1789409581332,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Growth differentiation factor 15 (GDF15) and fibroblast growth factor 21 (FGF21) are stress-induced cytokines increased in age-related and metabolic disorders. The aim of the present study was to analyze\u00a0the association between circulating concentrations of GDF15 and FGF21 in obesity and type 2 diabetes (T2D) in the context of aging. Serum samples from 405 participants (33 with normal weight and normoglycemia (NG), 156 with obesity and NG, 157 with obesity and impaired glucose tolerance (IGT), and 59 with obesity and T2D) aged 47\u2009\u00b1\u200913\u00a0years, were recruited to study the serum GDF15 and FGF21 concentrations and their relationship with obesity, T2D, and aging. Adipokines (leptin and adiponectin) and other cardiometabolic risk factors were also measured. The circulating concentrations of GDF15 and FGF21 were significantly increased with obesity and further increased with IGT and T2D. Both GDF15 and FGF21 showed positive associations with glucose (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.25,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001 and\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.40,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001, respectively) and insulin (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.16,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01 and\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.27,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001, respectively) levels. Similarly, GDF15 and FGF21 were positively correlated with age (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.55,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001 and\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u20090.15,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.01, respectively). Interestingly, the FGF21\/adiponectin and GDF15\/adiponectin ratios emerged as good biomarkers for the presence of T2D (AUC\u2009=\u20090.807 and 0.779, respectively). Our findings support that obesity, T2D, and aging increase the concentrations of both GDF15 and FGF21. Furthermore, GDF15 concentrations are more associated with aging while FGF21 levels are more related to the metabolic status. Finally, we propose the FGF21\/adiponectin ratio as a novel biomarker for the detection of the presence of T2D.\n                  <\/jats:p>","DOI":"10.1007\/s11357-025-01830-3","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:39:18Z","timestamp":1755614358000},"page":"2931-2944","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Different association of GDF15 and FGF21 with glycemic status and aging in the context of obesity"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-512X","authenticated-orcid":false,"given":"Laura","family":"Salm\u00f3n-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7513-7509","authenticated-orcid":false,"given":"Victoria","family":"Catal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-7220","authenticated-orcid":false,"given":"Beatriz","family":"Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1156-4904","authenticated-orcid":false,"given":"Maite","family":"Aguas-Ayesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2180-461X","authenticated-orcid":false,"given":"Amaia","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3441-1970","authenticated-orcid":false,"given":"Sara","family":"Becerril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Baixauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonsoles","family":"Guti\u00e9rrez-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2800-4735","authenticated-orcid":false,"given":"Carmen","family":"Mugueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-9455","authenticated-orcid":false,"given":"Inmaculada","family":"Colina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5748-0581","authenticated-orcid":false,"given":"Carolina M.","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3466-1291","authenticated-orcid":false,"given":"Camilo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-9465","authenticated-orcid":false,"given":"Javier","family":"Escalada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8305-7154","authenticated-orcid":false,"given":"Gema","family":"Fr\u00fchbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5601-1604","authenticated-orcid":false,"given":"Javier","family":"G\u00f3mez-Ambrosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"1","key":"1830_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"A Afshin","year":"2017","unstructured":"Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1614362.","journal-title":"N Engl J Med"},{"issue":"1","key":"1830_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14309\/ajg.0000000000001553","volume":"117","author":"VB Popov","year":"2022","unstructured":"Popov VB, Aytaman A, Alem\u00e1n JO. Obesity: the forgotten pandemic. Am J Gastroenterol. 2022;117(1):7\u201310. https:\/\/doi.org\/10.14309\/ajg.0000000000001553.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1830_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11154-023-09796-3","volume":"24","author":"L Salm\u00f3n-G\u00f3mez","year":"2023","unstructured":"Salm\u00f3n-G\u00f3mez L, Catal\u00e1n V, Fr\u00fchbeck G, G\u00f3mez-Ambrosi J. Relevance of body composition in phenotyping the obesities. Rev Endocr Metab Disord. 2023;24(5):809\u201323. https:\/\/doi.org\/10.1007\/s11154-023-09796-3.","journal-title":"Rev Endocr Metab Disord"},{"issue":"8","key":"1830_CR4","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/nu14081597","volume":"14","author":"V Catal\u00e1n","year":"2022","unstructured":"Catal\u00e1n V, Avil\u00e9s-Olmos I, Rodr\u00edguez A, Becerril S, Fern\u00e1ndez-Formoso JA, Kiortsis D, et al. Time to consider the \u201cexposome hypothesis\" in the development of the obesity pandemic. Nutrients. 2022;14(8):1597. https:\/\/doi.org\/10.3390\/nu14081597.","journal-title":"Nutrients"},{"issue":"2","key":"1830_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1017\/s0954422412000145","volume":"25","author":"A Lancha","year":"2012","unstructured":"Lancha A, Fr\u00fchbeck G, G\u00f3mez-Ambrosi J. Peripheral signalling involved in energy homeostasis control. Nutr Res Rev. 2012;25(2):223\u201348. https:\/\/doi.org\/10.1017\/s0954422412000145.","journal-title":"Nutr Res Rev"},{"issue":"1","key":"1830_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","volume":"34","author":"S Klein","year":"2022","unstructured":"Klein S, Gastaldelli A, Yki-J\u00e4rvinen H, Scherer PE. Why does obesity cause diabetes? Cell Metab. 2022;34(1):11\u201320. https:\/\/doi.org\/10.1016\/j.cmet.2021.12.012.","journal-title":"Cell Metab"},{"issue":"10382","key":"1830_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/s0140-6736(22)02403-5","volume":"401","author":"CM Perdomo","year":"2023","unstructured":"Perdomo CM, Cohen RV, Sumithran P, Cl\u00e9ment K, Fr\u00fchbeck G. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023;401(10382):1116\u201330. https:\/\/doi.org\/10.1016\/s0140-6736(22)02403-5.","journal-title":"Lancet"},{"issue":"1","key":"1830_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.7570\/jomes23008","volume":"32","author":"JY Park","year":"2023","unstructured":"Park JY. Weight loss prediction after metabolic and bariatric surgery. J Obes Metab Syndr. 2023;32(1):46\u201354. https:\/\/doi.org\/10.7570\/jomes23008.","journal-title":"J Obes Metab Syndr"},{"issue":"11","key":"1830_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.tem.2021.08.008","volume":"32","author":"S Keipert","year":"2021","unstructured":"Keipert S, Ost M. Stress-induced FGF21 and GDF15 in obesity and obesity resistance. Trends Endocrinol Metab. 2021;32(11):904\u201315. https:\/\/doi.org\/10.1016\/j.tem.2021.08.008.","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"1830_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41574-021-00529-7","volume":"17","author":"D Wang","year":"2021","unstructured":"Wang D, Day EA, Townsend LK, Djordjevic D, J\u00f8rgensen SB, Steinberg GR. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat Rev Endocrinol. 2021;17(10):592\u2013607. https:\/\/doi.org\/10.1038\/s41574-021-00529-7.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"1830_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","volume":"28","author":"VWW Tsai","year":"2018","unstructured":"Tsai VWW, Husaini Y, Sainsbury A, Brown DA, Breit SN. The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 2018;28(3):353\u201368. https:\/\/doi.org\/10.1016\/j.cmet.2018.07.018.","journal-title":"Cell Metab"},{"issue":"7968","key":"1830_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41586-023-06249-4","volume":"619","author":"D Wang","year":"2023","unstructured":"Wang D, Townsend LK, DesOrmeaux GJ, Frangos SM, Batchuluun B, Dumont L, et al. GDF15 promotes weight loss by enhancing energy expenditure in muscle. Nature. 2023;619(7968):143\u201350. https:\/\/doi.org\/10.1038\/s41586-023-06249-4.","journal-title":"Nature"},{"issue":"7675","key":"1830_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature24042","volume":"550","author":"JY Hsu","year":"2017","unstructured":"Hsu JY, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature. 2017;550(7675):255\u20139. https:\/\/doi.org\/10.1038\/nature24042.","journal-title":"Nature"},{"issue":"10","key":"1830_CR14","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm.4394","volume":"23","author":"L Yang","year":"2017","unstructured":"Yang L, Chang CC, Sun Z, Madsen D, Zhu H, Padkj\u00e6r SB, et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med. 2017;23(10):1158\u201366. https:\/\/doi.org\/10.1038\/nm.4394.","journal-title":"Nat Med"},{"issue":"10","key":"1830_CR15","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/nm.4393","volume":"23","author":"PJ Emmerson","year":"2017","unstructured":"Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 2017;23(10):1215\u20139. https:\/\/doi.org\/10.1038\/nm.4393.","journal-title":"Nat Med"},{"issue":"10","key":"1830_CR16","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/nm.4392","volume":"23","author":"SE Mullican","year":"2017","unstructured":"Mullican SE, Lin-Schmidt X, Chin CN, Chavez JA, Furman JL, Armstrong AA, et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 2017;23(10):1150\u20137. https:\/\/doi.org\/10.1038\/nm.4392.","journal-title":"Nat Med"},{"key":"1830_CR17","doi-asserted-by":"publisher","first-page":"102070","DOI":"10.1016\/j.molmet.2024.102070","volume":"91","author":"C Hes","year":"2024","unstructured":"Hes C, Gui LT, Bay A, Alvarez F, Katz P, Paul T, et al. GDNF family receptor alpha-like (GFRAL) expression is restricted to the caudal brainstem. Mol Metab. 2024;91:102070. https:\/\/doi.org\/10.1016\/j.molmet.2024.102070.","journal-title":"Mol Metab"},{"key":"1830_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101569","volume":"75","author":"M Conte","year":"2022","unstructured":"Conte M, Giuliani C, Chiariello A, Iannuzzi V, Franceschi C, Salvioli S. GDF15, an emerging key player in human aging. Ageing Res Rev. 2022;75: 101569. https:\/\/doi.org\/10.1016\/j.arr.2022.101569.","journal-title":"Ageing Res Rev"},{"issue":"5","key":"1830_CR19","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/gerona\/gly153","volume":"74","author":"M Conte","year":"2019","unstructured":"Conte M, Ostan R, Fabbri C, Santoro A, Guidarelli G, Vitale G, et al. Human aging and longevity are characterized by high levels of mitokines. J Gerontol A Biol Sci Med Sci. 2019;74(5):600\u20137. https:\/\/doi.org\/10.1093\/gerona\/gly153.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"1830_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12799","volume":"17","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Biancotto A, Moaddel R, Moore AZ, Gonzalez-Freire M, Aon MA, et al. Plasma proteomic signature of age in healthy humans. Aging Cell. 2018;17(5): e12799. https:\/\/doi.org\/10.1111\/acel.12799.","journal-title":"Aging Cell"},{"issue":"2","key":"1830_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ijo.2015.242","volume":"40","author":"VW Tsai","year":"2016","unstructured":"Tsai VW, Lin S, Brown DA, Salis A, Breit SN. Anorexia-cachexia and obesity treatment may be two sides of the same coin: role of the TGF-b superfamily cytokine MIC-1\/GDF15. Int J Obes (Lond). 2016;40(2):193\u20137. https:\/\/doi.org\/10.1038\/ijo.2015.242.","journal-title":"Int J Obes (Lond)"},{"key":"1830_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan8732","author":"Y Xiong","year":"2017","unstructured":"Xiong Y, Walker K, Min X, Hale C, Tran T, Komorowski R, et al. Long-acting MIC-1\/GDF15 molecules to treat obesity: evidence from mice to monkeys. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aan8732.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1830_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00125-018-4751-7","volume":"62","author":"X Bao","year":"2019","unstructured":"Bao X, Born\u00e9 Y, Muhammad IF, Nilsson J, Lind L, Melander O, et al. Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malm\u00f6 diet and cancer-cardiovascular cohort. Diabetologia. 2019;62(1):78\u201386. https:\/\/doi.org\/10.1007\/s00125-018-4751-7.","journal-title":"Diabetologia"},{"issue":"5","key":"1830_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s11684-019-0711-y","volume":"13","author":"X Li","year":"2019","unstructured":"Li X. The FGF metabolic axis. Front Med. 2019;13(5):511\u201330. https:\/\/doi.org\/10.1007\/s11684-019-0711-y.","journal-title":"Front Med"},{"issue":"3","key":"1830_CR25","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","volume":"3","author":"KH Flippo","year":"2021","unstructured":"Flippo KH, Potthoff MJ. Metabolic messengers: FGF21. Nat Metab. 2021;3(3):309\u201317. https:\/\/doi.org\/10.1038\/s42255-021-00354-2.","journal-title":"Nat Metab"},{"issue":"2","key":"1830_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","volume":"29","author":"SA Kliewer","year":"2019","unstructured":"Kliewer SA, Mangelsdorf DJ. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab. 2019;29(2):246\u201353. https:\/\/doi.org\/10.1016\/j.cmet.2019.01.004.","journal-title":"Cell Metab"},{"issue":"4","key":"1830_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4093\/dmj.2014.38.4.245","volume":"38","author":"KH Kim","year":"2014","unstructured":"Kim KH, Lee MS. FGF21 as a stress hormone: the roles of FGF21 in stress adaptation and the treatment of metabolic diseases. Diabetes Metab J. 2014;38(4):245\u201351. https:\/\/doi.org\/10.4093\/dmj.2014.38.4.245.","journal-title":"Diabetes Metab J"},{"issue":"3","key":"1830_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.clnu.2016.04.027","volume":"36","author":"J G\u00f3mez-Ambrosi","year":"2017","unstructured":"G\u00f3mez-Ambrosi J, Gallego-Escuredo JM, Catal\u00e1n V, Rodr\u00edguez A, Domingo P, Moncada R, et al. FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss. Clin Nutr. 2017;36(3):861\u20138. https:\/\/doi.org\/10.1016\/j.clnu.2016.04.027.","journal-title":"Clin Nutr"},{"issue":"11","key":"1830_CR29","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","volume":"59","author":"FM Fisher","year":"2010","unstructured":"Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 2010;59(11):2781\u20139. https:\/\/doi.org\/10.2337\/db10-0193.","journal-title":"Diabetes"},{"key":"1830_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.655575","volume":"8","author":"J Yan","year":"2021","unstructured":"Yan J, Nie Y, Cao J, Luo M, Yan M, Chen Z, et al. The roles and pharmacological effects of FGF21 in preventing aging-associated metabolic diseases. Front Cardiovasc Med. 2021;8: 655575. https:\/\/doi.org\/10.3389\/fcvm.2021.655575.","journal-title":"Front Cardiovasc Med"},{"issue":"Suppl 1","key":"1830_CR31","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","volume":"47","author":"American diabetes association","year":"2024","unstructured":"American diabetes association. Diagnosis and classification of diabetes: standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-s42. https:\/\/doi.org\/10.2337\/dc24-S002.","journal-title":"Diabetes Care"},{"issue":"2","key":"1830_CR32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ijo.2011.100","volume":"36","author":"J G\u00f3mez-Ambrosi","year":"2012","unstructured":"G\u00f3mez-Ambrosi J, Silva C, Galofr\u00e9 JC, Escalada J, Santos S, Mill\u00e1n D, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond). 2012;36(2):286\u201394. https:\/\/doi.org\/10.1038\/ijo.2011.100.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"1830_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.clnu.2017.01.010","volume":"37","author":"J G\u00f3mez-Ambrosi","year":"2018","unstructured":"G\u00f3mez-Ambrosi J, Gonz\u00e1lez-Crespo I, Catal\u00e1n V, Rodr\u00edguez A, Moncada R, Valent\u00ed V, et al. Clinical usefulness of abdominal bioimpedance (ViScan) in the determination of visceral fat and its application in the diagnosis and management of obesity and its comorbidities. Clin Nutr. 2018;37(2):580\u20139. https:\/\/doi.org\/10.1016\/j.clnu.2017.01.010.","journal-title":"Clin Nutr"},{"issue":"1","key":"1830_CR34","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1038\/s41598-017-06997-0","volume":"7","author":"G Fr\u00fchbeck","year":"2017","unstructured":"Fr\u00fchbeck G, Catal\u00e1n V, Rodr\u00edguez A, Ram\u00edrez B, Becerril S, Salvador J, et al. Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome. Sci Rep. 2017;7(1):6619. https:\/\/doi.org\/10.1038\/s41598-017-06997-0.","journal-title":"Sci Rep"},{"issue":"2","key":"1830_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0016-6480(02)00072-2","volume":"128","author":"FJ Muruz\u00e1bal","year":"2002","unstructured":"Muruz\u00e1bal FJ, Fr\u00fchbeck G, G\u00f3mez-Ambrosi J, Archanco M, Burrell MA. Immunocytochemical detection of leptin in non-mammalian vertebrate stomach. Gen Comp Endocrinol. 2002;128(2):149\u201352. https:\/\/doi.org\/10.1016\/s0016-6480(02)00072-2.","journal-title":"Gen Comp Endocrinol"},{"issue":"6","key":"1830_CR36","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/hep.510300604","volume":"30","author":"P Angulo","year":"1999","unstructured":"Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30(6):1356\u201362. https:\/\/doi.org\/10.1002\/hep.510300604.","journal-title":"Hepatology"},{"issue":"7","key":"1830_CR37","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/clinchem\/37.7.1273","volume":"37","author":"M Conti","year":"1991","unstructured":"Conti M, Morand PC, Levillain P, Lemonnier A. Improved fluorometric determination of malonaldehyde. Clin Chem. 1991;37(7):1273\u20135.","journal-title":"Clin Chem"},{"issue":"1","key":"1830_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32\u20135. https:\/\/doi.org\/10.1002\/1097-0142(1950)3:1%3c32::aid-cncr2820030106%3e3.0.co;2-3.","journal-title":"Cancer"},{"issue":"2","key":"1830_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.cmet.2023.01.002","volume":"35","author":"SN Breit","year":"2023","unstructured":"Breit SN, Brown DA, Tsai VWW. GDF15 analogs as obesity therapeutics. Cell Metab. 2023;35(2):227\u20138. https:\/\/doi.org\/10.1016\/j.cmet.2023.01.002.","journal-title":"Cell Metab"},{"issue":"9","key":"1830_CR40","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/jcmm.17725","volume":"27","author":"M Asrih","year":"2023","unstructured":"Asrih M, Wei S, Nguyen TT, Yi HS, Ryu D, Gariani K. Overview of growth differentiation factor 15 in metabolic syndrome. J Cell Mol Med. 2023;27(9):1157\u201367. https:\/\/doi.org\/10.1111\/jcmm.17725.","journal-title":"J Cell Mol Med"},{"issue":"11","key":"1830_CR41","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.tem.2022.08.004","volume":"33","author":"D Aguilar-Recarte","year":"2022","unstructured":"Aguilar-Recarte D, Barroso E, Palomer X, Wahli W, V\u00e1zquez-Carrera M. Knocking on GDF15\u2019s door for the treatment of type 2 diabetes mellitus. Trends Endocrinol Metab. 2022;33(11):741\u201354. https:\/\/doi.org\/10.1016\/j.tem.2022.08.004.","journal-title":"Trends Endocrinol Metab"},{"key":"1830_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1220426","volume":"14","author":"M Yang","year":"2023","unstructured":"Yang M, Liu C, Jiang N, Liu Y, Luo S, Li C, et al. Fibroblast growth factor 21 in metabolic syndrome. Front Endocrinol (Lausanne). 2023;14: 1220426. https:\/\/doi.org\/10.3389\/fendo.2023.1220426.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1830_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.atherosclerosis.2018.12.001","volume":"281","author":"O Ajala","year":"2019","unstructured":"Ajala O, Mora S. Fibroblast growth factor-21 levels in metabolic syndrome: another instrument in a widening tool belt? Atherosclerosis. 2019;281:143\u20134. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.12.001.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1830_CR44","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","volume":"16","author":"L Geng","year":"2020","unstructured":"Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol. 2020;16(11):654\u201367. https:\/\/doi.org\/10.1038\/s41574-020-0386-0.","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"1830_CR45","doi-asserted-by":"publisher","first-page":"472","DOI":"10.4093\/dmj.2014.38.6.472","volume":"38","author":"JH Hong","year":"2014","unstructured":"Hong JH, Chung HK, Park HY, Joung KH, Lee JH, Jung JG, et al. GDF15 is a novel biomarker for impaired fasting glucose. Diabetes Metab J. 2014;38(6):472\u20139. https:\/\/doi.org\/10.4093\/dmj.2014.38.6.472.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"1830_CR46","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1038\/s41467-023-38148-7","volume":"14","author":"RC Slieker","year":"2023","unstructured":"Slieker RC, Donnelly LA, Akalestou E, Lopez-Noriega L, Melhem R, G\u00fcne\u015f A, et al. Identification of biomarkers for glycaemic deterioration in type 2 diabetes. Nat Commun. 2023;14(1):2533. https:\/\/doi.org\/10.1038\/s41467-023-38148-7.","journal-title":"Nat Commun"},{"key":"1830_CR47","doi-asserted-by":"publisher","first-page":"837575","DOI":"10.3389\/fragi.2022.837575","volume":"3","author":"BD Pence","year":"2022","unstructured":"Pence BD. Growth differentiation factor-15 in immunity and aging. Front Aging. 2022;3:837575. https:\/\/doi.org\/10.3389\/fragi.2022.837575.","journal-title":"Front Aging"},{"issue":"3","key":"1830_CR48","doi-asserted-by":"publisher","first-page":"9776","DOI":"10.1007\/s11357-015-9776-y","volume":"37","author":"F Sanchis-Gomar","year":"2015","unstructured":"Sanchis-Gomar F, Pareja-Galeano H, Santos-Lozano A, Garatachea N, Fiuza-Luces C, Venturini L, et al. A preliminary candidate approach identifies the combination of chemerin, fetuin-A, and fibroblast growth factors 19 and 21 as a potential biomarker panel of successful aging. Age. 2015;37(3):9776. https:\/\/doi.org\/10.1007\/s11357-015-9776-y.","journal-title":"Age"},{"key":"1830_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2021.111228","volume":"146","author":"H Liu","year":"2021","unstructured":"Liu H, Huang Y, Lyu Y, Dai W, Tong Y, Li Y. GDF15 as a biomarker of ageing. Exp Gerontol. 2021;146: 111228. https:\/\/doi.org\/10.1016\/j.exger.2021.111228.","journal-title":"Exp Gerontol"},{"key":"1830_CR50","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-physiol-022020-045449","volume":"83","author":"SN Breit","year":"2021","unstructured":"Breit SN, Brown DA, Tsai VW. The GDF15-GFRAL pathway in health and metabolic disease: friend or foe? Annu Rev Physiol. 2021;83:127\u201351. https:\/\/doi.org\/10.1146\/annurev-physiol-022020-045449.","journal-title":"Annu Rev Physiol"},{"key":"1830_CR51","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-physiol-021115-105339","volume":"78","author":"FM Fisher","year":"2016","unstructured":"Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol. 2016;78:223\u201341. https:\/\/doi.org\/10.1146\/annurev-physiol-021115-105339.","journal-title":"Annu Rev Physiol"},{"issue":"2","key":"1830_CR52","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/nu11020454","volume":"11","author":"G Fr\u00fchbeck","year":"2019","unstructured":"Fr\u00fchbeck G, Catal\u00e1n V, Rodr\u00edguez A, Ram\u00edrez B, Becerril S, Salvador J, et al. Adiponectin-leptin ratio is a functional biomarker of adipose tissue inflammation. Nutrients. 2019;11(2):454. https:\/\/doi.org\/10.3390\/nu11020454.","journal-title":"Nutrients"},{"issue":"8","key":"1830_CR53","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/bf03346639","volume":"33","author":"J Zaletel","year":"2010","unstructured":"Zaletel J, Barlovic DP, Prezelj J. Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with type 2 diabetes. J Endocrinol Invest. 2010;33(8):514\u20138. https:\/\/doi.org\/10.1007\/bf03346639.","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1830_CR54","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cmet.2016.04.011","volume":"23","author":"JH Stern","year":"2016","unstructured":"Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23(5):770\u201384. https:\/\/doi.org\/10.1016\/j.cmet.2016.04.011.","journal-title":"Cell Metab"},{"issue":"1","key":"1830_CR55","doi-asserted-by":"publisher","first-page":"17718","DOI":"10.1038\/s41598-023-43550-8","volume":"13","author":"G Aisike","year":"2023","unstructured":"Aisike G, Kuerbanjiang M, Muheyati D, Zaibibuli K, Lv MX, Han J. Correlation analysis of obesity phenotypes with leptin and adiponectin. Sci Rep. 2023;13(1):17718. https:\/\/doi.org\/10.1038\/s41598-023-43550-8.","journal-title":"Sci Rep"},{"issue":"1","key":"1830_CR56","doi-asserted-by":"publisher","DOI":"10.2174\/1573399817666210104101739","volume":"18","author":"D Roy","year":"2022","unstructured":"Roy D, Purohit P, Modi A, Khokhar M, Shukla RKG, Chaudhary R, et al. Growth differentiation factor-15 as a biomarker of obese pre-diabetes and type 2 diabetes mellitus in Indian subjects: a case-control study. Curr Diabetes Rev. 2022;18(1): e010321189862. https:\/\/doi.org\/10.2174\/1573399817666210104101739.","journal-title":"Curr Diabetes Rev"},{"issue":"7795","key":"1830_CR57","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","volume":"578","author":"AP Coll","year":"2020","unstructured":"Coll AP, Chen M, Taskar P, Rimmington D, Patel S, Tadross JA, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020;578(7795):444\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1911-y.","journal-title":"Nature"},{"issue":"1","key":"1830_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01351-1","volume":"20","author":"D Liu","year":"2021","unstructured":"Liu D, Wu L, Gao Q, Long X, Hou X, Qian L, et al. FGF21\/adiponectin ratio predicts deterioration in glycemia: a 4.6-year prospective study in China. Cardiovasc Diabetol. 2021;20(1): 157. https:\/\/doi.org\/10.1186\/s12933-021-01351-1.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1830_CR59","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12020-021-02632-1","volume":"72","author":"X Wu","year":"2021","unstructured":"Wu X, Xuan W, You L, Lian H, Li F, Zhang X, et al. Associations of GDF-15 and GDF-15\/adiponectin ratio with odds of type 2 diabetes in the Chinese population. Endocrine. 2021;72(2):423\u201336. https:\/\/doi.org\/10.1007\/s12020-021-02632-1.","journal-title":"Endocrine"},{"key":"1830_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1146376","volume":"14","author":"S Zheng","year":"2023","unstructured":"Zheng S, Shen M, Qian Y, Li S, Chen Y, Jiang H, et al. Growth differentiation factor-15\/adiponectin ratio as a potential biomarker for metabolic syndrome in Han Chinese. Front Endocrinol (Lausanne). 2023;14: 1146376. https:\/\/doi.org\/10.3389\/fendo.2023.1146376.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01830-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01830-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01830-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:40:31Z","timestamp":1773049231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01830-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01830-3","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GF declares payment of honoraria for lectures from Novo Nordisk as a member of the OPEN Spain Initiative as well as payment of honoraria for attendance at advisory boards from Lilly, Novo Nordisk, Regeneron, and AstraZeneca and declares no competing interest, financial or nonfinancial, related to this work. The other authors declared no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}